Interesting new @thelancet.bsky.social study by H. Naci @lsehealthpolicy.bsky.social & I. Papanicolas @Brown Study shows tradeoffs in England of covering costly new drugs at the expense of not covering existing drugs/services in NHS. Result: Less health gains www.thelancet.com/journals/lan...

Access to essential medicines is not improving over the past 4 decades with existing tools. "The gap between richer (high- and upper-middle-income) and poorer (lower-middle- and low-income) countries remained largely unchanged over time." www.healthaffairs.org/doi/epdf/10....

Reductions in prices associated with the Medicare Drug Price Negotiation Program differed widely across the 10 drugs. The negotiated prices of all products but 1 remained above list prices in peer countries. ja.ma/3B9rsXF

New paper out at @jamacurrent.bsky.social led by @ojwouters.bsky.social on the empirical assumptions underlying differential protection for biologics & small-molecule drugs. Upshot: We found no good evidence supporting differential treatment by FDA (or under IRA). jamanetwork.com/journals/jam...

Relevant to accelerated approval, new DCE from former @portalresearch.org fellow Huseyin Naci et al examined patient views on survival benefit for cancer drugs: "individuals expressed strong preferences for certainty that a cancer drug would offer survival benefit" www.thelancet.com/journals/lan...